Brief: Tempest Reports First Quarter 2023 Financial Results And Provides Business Update
10/05/2023 22:53
Tempest Therapeutics Inc TPST.O :
* TEMPEST REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
AND PROVIDES BUSINESS UPDATE
* TEMPEST THERAPEUTICS INC - NET LOSS AND NET LOSS PER SHARE
FOR
QUARTER ENDED MARCH 31, 2023 WERE $7.6 MILLION AND $0.55,
RESPECTIVELY
* TEMPEST THERAPEUTICS INC - TEMPEST EXPECTS TO HAVE
SUFFICIENT
RESOURCES TO FUND OPERATIONS THROUGH Q2 OF 2024.
Source text for Eikon: ID:nGNX14877m
Further company coverage: TPST.O
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T